CVS Health Corp.

After three years, Amgen has to pay Regeneron Pharmaceuticals more than $400m in damages after a federal court jury found the biotech liable for violating antitrust and tort laws by allegedly using ag

The epic contest between Eli Lilly and Novo Nordisk for GLP-1 agonist supremacy is full of twists and turns. Just as one appears to dominate, the tables turn again. Lilly Unrewarded For Success Lilly

Eli Lilly has made significant headway in obesity in the first quarter of 2025, recording big year-over-year revenue gains from the GIP/GLP-1 receptor agonist Zepbound (tirzepatide) and successful Pha

Reflecting the growing willingness among biopharma executives to openly voice concerns about the Trump Administration’s policies, Eli Lilly CEO David Ricks started out the firm’s first quarter earning